You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Dow
McKesson
Boehringer Ingelheim
Colorcon

Last Updated: January 24, 2021

DrugPatentWatch Database Preview

Patent: 9,134,329

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,134,329
Title:Compositions and methods for drug-sensitization or inhibition of a cancer cell
Abstract: The disclosure provides rifamycin and rifamycin derivative compositions, including rifabutin and rifabutin derivative compositions able to cause drug-sensitization in a cancer cell or inhibition of a cancer cell. The disclosure also provides methods of administering such compositions to cancer cells to sensitize them to drugs, such as chemotherapeutics, or directly inhibit them. The disclosure also provides methods of administering such compositions to increase reactive oxygen species (ROS), particularly superoxides, in cancer cells. The disclosure further provides methods of determining whether a cancer will respond to chemotherapeutics and whether to administer rifamycin or a rifamycin derivative based on ROS levels in cancer cells of a patient.
Inventor(s): Sacchettini; James (College Station, TX), Zhou; Niam (College Station, TX), Baker; Dwight (College Station, TX), Maxwell; Steven A. (College Station, TX), Wallis; Deeann (College Station, TX)
Assignee: The Texas A&M University System (College Station, TX)
Application Number:14/322,727
Patent Claims:see list of patent claims

Details for Patent 9,134,329

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial The Texas A&M University System (College Station, TX) 2032-08-30 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,134,329

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2014036309   Start Trial
United States of America 2014314878   Start Trial
United States of America 2015017673   Start Trial
United States of America 2016038460   Start Trial
United States of America 2017071905   Start Trial
United States of America 9539237   Start Trial
United States of America 9867807   Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Mallinckrodt
Colorcon
Dow
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.